

## **SUPPLEMENTARY MATERIAL RELATED TO**

# **The Effect of Antioxidant Supplementation in Idiopathic Tinnitus: A randomised, Double-Blind, Placebo Controlled Trial**

**Anna I. Petridou<sup>1</sup>, Eleftheria T. Zagora<sup>2</sup>, Petros Petridis<sup>3</sup>, George S. Korres<sup>4</sup>, Maria Gazouli<sup>5</sup>, Ioannis Xenelis<sup>1</sup>, Efthymios Kyrodimos<sup>1</sup>, Georgia Kontothanasi<sup>2</sup> and Andriana C. Kaliora<sup>6,\*</sup>**

<sup>1</sup> 1st ENT Department, School of Medicine, National and Kapodistrian University of Athens, Hippokration Hospital, 11527 Athens, Greece; anna.petridou@outlook.com; cxeneli@yahoo.com; timkirodimos@hotmail.com

<sup>2</sup> ENT Department, General Hospital of Nikaia “Agios Panteleimon”, 18454 Nikaia, Greece; zagoraeleftheria@gmail.com; georgia.kontothanasi@gmail.com

<sup>3</sup> ENT Department, St. Johannes Hospital, 44137 Dortmund, Germany; petridisppeter@hotmail.com

<sup>4</sup> 2nd ENT Department, School of Medicine, National and Kapodistrian University of Athens, Attikon Hospital, 12462 Chaidari, Greece; gfkorres@gmail.com

<sup>5</sup> Department of Biology, School of Medicine, National and Kapodistrian University of Athens , 11527 Athens, Greece; maria.gazouli@gmail.com

<sup>6</sup> Department of Dietetics and Nutritional Science, School of Health Science and Education, Harokopio University, 17671 Athens, Greece; [akaliora@hua.gr](mailto:akaliora@hua.gr); [andrianakaliora@gmail.com](mailto:andrianakaliora@gmail.com)

\* Correspondence: [akaliora@hua.gr](mailto:akaliora@hua.gr); [andrianakaliora@gmail.com](mailto:andrianakaliora@gmail.com). Tel.: +302109549226

**Table S1.** Sample characteristics by study group

	Placebo group N=29	Antioxidant group N=34	P
	N (%)	N (%)	
<b>Age (years), mean (SD)</b>	59.2 (13.5)	56.5 (12.4)	0.416‡
<b>Sex</b>			
Men	16 (55.2)	25 (73.5)	0.128+
Women	13 (44.8)	9 (26.5)	
<b>Marital status</b>			
Married	18 (62.1)	21 (61.8)	
Unmarried	5 (17.2)	8 (23.5)	0.182++
Widowed	5 (17.2)	1 (2.9)	
Divorced	1 (3.4)	4 (11.8)	
<b>Education (years)</b>			
1-9	10 (34.5)	4 (11.8)	
10-12	10 (34.5)	17 (50)	0.093+
>12	9 (31)	13 (38.2)	
<b>Smoking</b>			
No	14 (48.3)	14 (41.2)	
Yes	5 (17.2)	9 (26.5)	0.671+
In the past	10 (34.5)	11 (32.4)	
<b>Passive smoking</b>	5 (17.2)	9 (26.5)	0.308+
<b>Medical history</b>			
Hypercholesterolemia	13 (44.8)	11 (32.4)	0.310+
Diabetes	3 (10.3)	1 (2.9)	0.326++
Hypertension	12 (41.4)	8 (23.5)	0.129+
Hypothyroidism	7 (24.1)	3 (8.8)	0.165++
<b>Psychological situation</b>			
HADS-A, mean (SD)	5.9 (4.9)	4.5 (3.3)	0.175‡
HADS-D, mean (SD)	4.1 (3.6)	4 (3.5)	0.965‡
CES-D, mean (SD)	12.4 (9.3)	16.1 (10.5)	0.156‡
<b>Physical Activity</b>			
MET-minutes/week, mean (SD)	2582.4 (2251.0)	2158.3 (2262.4)	0.460‡
<b>Anthropometrics</b>			
BMI (kg/m <sup>2</sup> ), mean (SD)	27 (5.5)	27.8 (4.3)	0.562‡
Waist circumference, mean (SD)	96.9 (9.4)	101.9 (10.8)	0.061‡
Hip circumference, mean (SD)	104.4 (7.9)	104.2 (8.9)	0.910‡
<b>Biochemical profile</b>			
Uric acid (mg/dl), mean (SD)	5.19 (1.04)	5.3 (0.87)	0.695‡
Urea (mg/dl), mean (SD)	37.7 (12.2)	33.1 (9.5)	0.104‡
Creatinine (mg/dl), mean (SD)	0.85 (0.15)	0.85 (0.16)	0.963‡
Na (mmol/L), mean (SD)	141.3 (1.5)	141.5 (2.1)	0.662‡
K (mmol/L), mean (SD)	4.36 (0.42)	4.45 (0.37)	0.453‡
AST (IU/L), mean (SD)	20.8 (6.1)	20.8 (6.1)	0.970‡
ALT (IU/L), mean (SD)	35.3 (12.3)	35.6 (14.3)	0.934‡
γ-GT (IU/L), mean (SD)	36.7 (19.2)	35.3 (16.7)	0.806‡
Albumin (g/dl), mean (SD)	4.16 (0.36)	4.24 (0.28)	0.421‡
HbA1c (%), mean (SD)	5.69 (0.51)	5.66 (0.32)	0.85‡
Glucose (mg/dl), mean (SD)	93.8 (12.8)	96.7 (14)	0.422‡

Cholesterol (mg/dl), mean (SD)	208 (39.8)	202.9 (43.3)	0.664‡
HDL (mg/dl), mean (SD)	59.9 (16.2)	55 (13.7)	0.258‡
LDL (mg/dl), mean (SD)	116.5 (32)	130.7 (36.3)	0.162‡
Triglycerides (mg/dl), mean (SD)	153.1 (150)	93.7 (37.9)	0.083‡
Atherogenic index, mean (SD)	3.84 (1.48)	3.89 (0.86)	0.876‡
CRP (mg/L), mean (SD)	2.6 (2.67)	2.24 (1.54)	0.585‡

\*Pearson's chi-square test; ‡Fisher's exact test; †Student's t-test

**Table S2** MedDietScore, antioxidant food consumption frequency and macronutrient intake by study group. The results are given as N (%) of the total number.

	Group				<i>P</i>	
	Placebo		Antioxidant			
	N	%	N	%		
<b>MedDietScore, mean (SD)</b>	31.0 (3.6)		31.2 (5.6)		0.825 <sup>+</sup>	
<b>Energy (kcal), mean (SD)</b>	1500.5 (534.4)		1637.1 (646.3)		0.370 <sup>+</sup>	
<b>Proteins (gr), mean (SD)</b>	64.9 (27.1)		64.7 (32)		0.987 <sup>+</sup>	
<b>Carbohydrates (gr), mean (SD)</b>	111.4 (66.1)		146.9 (89.6)		0.082 <sup>+</sup>	
<b>Fat (gr), mean (SD)</b>	75.3 (34.6)		80.9 (28.5)		0.484 <sup>+</sup>	
<b>Coffee consumption</b>	Never/Rarely	3	10.3	6	17.6	
	1-3 times/month	4	13.8	1	2.9	
	1-2 times/week	3	10.3	3	8.8	
	3-6 times/week	1	3.4	4	11.8	
	Once/day	5	17.2	6	17.6	
	>=twice/day	13	44.8	14	41.2	
<b>Consumption of herbal beverages</b>	Never/Rarely	8	27.6	17	50.0	
	1-3 times/month	7	24.1	3	8.8	
	1-2 times/week	3	10.3	3	8.8	
	3-6 times/week	5	17.2	5	14.7	
	Once/day	6	20.7	5	14.7	
	>=twice/day	0	0,0	1	2.9	
<b>Consumption of chocolate</b>	Never/Rarely	8	27.6	11	32.4	
	1-3 times/month	5	17.2	10	29.4	
	1-2 times/week	12	41.4	10	29.4	
	3-6 times/week	2	6.9	2	5.9	
	Once/day	2	6.9	1	2.9	
	>=twice/day	0	0	0	0	
<b>Consumption of wine</b>	Never/Rarely	10	34.5	6	17.6	
	1-3 times/month	9	31.0	9	26.5	
	1-2 times/week	4	13.8	13	38.2	
	3-6 times/week	1	3.4	3	8.8	
	Once/day	1	3.4	3	8.8	
	>=twice/day	4	13.8	0	0	

<sup>+</sup>Student's t-test <sup>++</sup>Fisher's exact test

**Table S3** Anthropometrics at baseline and at follow up. Values are expressed as the mean  $\pm$  SD.

		Pre	Post	Change	P <sup>1</sup>	P <sup>2</sup>
		Mean (SD)	Mean (SD)	Mean (SD)		
<b>Weight (kg)</b>	Placebo	77 (12.8)	74.7 (14.7)	-2.3 (11.7)	0.098	0.120
	Antioxidant	83 (14.2)	84.1 (14.3)	1.1 (2.2)	0.632	
<b>BMI (kg/m<sup>2</sup>)</b>	Placebo	27 (5.5)	26.2 (4.6)	-0.8 (5)	0.083	0.125
	Antioxidant	27.8 (4.3)	28 (4.2)	0.2 (0.7)	0.724	
<b>Waist circumference (cm)</b>	Placebo	96.9 (9.4)	97.7 (10.1)	0.8 (2.9)	0.471	0.722
	Antioxidant	101.9 (10.8)	103 (10.6)	1.1 (3.4)	0.800	
<b>Hip circumference (cm)</b>	Placebo	104.4 (7.9)	104.6 (8.5)	0.2 (1)	0.726	0.140
	Antioxidant	104.2 (8.9)	104.6 (9)	0.4 (1.2)	0.092	

<sup>1</sup>p-value for the time effect <sup>2</sup>p-value from repeated measurements ANOVA. The effects reported include differences between the groups in the degree of change.

**Table S4** Biochemical parameters at baseline and at follow up.

	Group	Pre		Post		Change	
		Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	Mean (SD)	P <sup>1</sup>
4							
<b>Hematocrit(%)</b>	Placebo	42.1 (3.3)	43.2 (40.1;44.1)	1.3 (4.3)	42 (39.2; 44.2)	-0.8 (4.3)	0.924
	Antioxidant	43.7 (3.4)	44.5 (42.7;45.7)	42.7 (3.4)	43.6 (41; 45.3)	-1.1 (2.5)	0.124
<b>Cholesterol (mg/dl)</b>	Placebo	208 (39.8)	208 (177;238)	221.1(20.3)	216.5(206.5;234)	13.1(20.5)	0.737
	Antioxidant	202.9(43.3)	190 (177.5;240)	214.1(41.2)	212 (175; 246)	11.2(24.5)	0.179
<b>HDL (mg/dl)</b>	Placebo	59.9 (16.2)	57 (46; 74)	55 (13.2)	53 (45.5; 65.5)	-4.9 (10.4)	0.687
	Antioxidant	55 (13.7)	53 (48; 58)	56.5 (15.4)	58 (45; 65)	1.5 (7)	0.097
<b>LDL (mg/dl)</b>	Placebo	116.5 (32)	114 (92; 143)	140.4(20.4)	146 (120; 151.5)	23.9(19.7)	0.059
	Antioxidant	130.7(36.3)	117 (108; 159)	143 (35.2)	142 (120; 178)	12.3(23.3)	0.026
<b>Triglycerides (mg/dl)</b>	Placebo	153.1 (150)	93 (75; 166)	129.4 (52)	118.5 (92; 156)	-23.8(28.7)	0.083
	Antioxidant	93.7 (37.9)	95 (66; 119)	89 (34.4)	89 (67; 100)	-4.7 (40.4)	0.835
<b>Atherogenic index</b>	Placebo	3.84 (1.48)	3.4 (2.9; 4.4)	4.25 (1.24)	4 (3.4; 4.75)	0.41(1.58)	0.637
	Antioxidant	3.89 (0.86)	3.6 (3.3; 4.4)	4.09 (1.27)	3.7 (3.2; 4.8)	0.2 (0.7)	0.057
<b>Glucose (mg/dl)</b>	Placebo	93.8 (12.8)	89 (87; 102)	96.4 (17.2)	89.5 (87; 106)	2.6 (10.5)	0.087
	Antioxidant	96.7 (14)	94 (87; 102)	90.8 (10.3)	87 (84; 98)	-5.9 (8.8)	0.915
<b>CRP (mg/L)</b>	Placebo	2.6 (2.67)	1.6 (1.1; 2.9)	4.85 (4.1)	3.45 (2.2; 6.9)	2.3 (2.4)	0.970
	Antioxidant	2.24 (1.54)	1.75 (1.1; 3.05)	2.71 (2.12)	2.2 (1.4; 3.4)	0.5 (3.1)	0.510

<sup>1</sup>p-value for the time effect (using logarithmic transformations); <sup>2</sup>p-value from repeated measurements ANOVA. The effects reported include differences between the groups in the degree of change (using logarithmic transformations).

**Table S5** Macro- and micronutrient intake at baseline and at follow-up.

	Group	Pre		Post		Change	<i>p</i> <sup>1</sup>	<i>p</i> <sup>2</sup>
		Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	Mean (SD)		
<b>Energy (kcal)</b>	Placebo	1500.5 (534.4)	1371.8 (1086;1678)	1488.8 (480.9)	1382.6 (1200; 1567)	-11.7 (231.8)	0.622	0.123
	Antioxidant	1637.1 (646.3)	1388.9 (1172; 1910)	1488.4 (380.7)	1484.3 (1144; 1741)	-148.6(595.8)	0.077	
<b>Proteins (gr)</b>	Placebo	64.9 (27.1)	58.8 (46.5; 80)	64.8 (26.9)	57.8 (50; 80.2)	-0.1 (10.4)	0.852	0.168
	Antioxidant	64.7 (32)	53.6 (45; 70)	55.9 (20.9)	51.9 (42.3; 67.9)	-8.9 (34.7)	0.063	
<b>Carbohydrates (gr)</b>	Placebo	111.4 (66.1)	100 (64.7; 125.2)	122.3 (69.3)	110.3 (83.4; 134)	10.9 (31.7)	0.401	0.099
	Antioxidant	146.9 (89.6)	114.4 (94.6; 57.1)	128.8 (58.4)	120 (91.4; 149.3)	-18.1 (75.5)	0.121	
<b>Fat (gr)</b>	Placebo	75.3 (34.6)	69.1 (60; 77.5)	70.2 (31.1)	67 (50; 75.6)	-5.1 (11.2)	0.975	0.535
	Antioxidant	80.9 (28.5)	75.3 (65; 100)	78.1 (25.6)	80 (60; 94.1)	-2.8 (24.9)	0.368	
<b>b-carotene (μg)</b>	Placebo	2082.2 (3341.2)	269.1 (68.5; 3615)	1892.4 (2838.9)	590.3 (125.1;2610.9)	-189.8(1130.5)	0.074	0.247
	Antioxidant	1238.2 (2404)	149.9 (75.8; 759.9)	2458.4 (8054.4)	265.4 (74.5; 1180.3)	1220.3(7810.3)	0.729	
<b>Vitamin A (μg)</b>	Placebo	329 (326.9)	212.4 (124.8; 460.6)	305.4 (229.7)	242.9 (140.6;366)	-23.6 (228.4)	0.177	0.252
	Antioxidant	257.9 (229.5)	192.7 (118.5;281.4)	444.7 (868.3)	172.6 (90.1;337.5)	186.8 (813.6)	0.860	
<b>Vitamin C (mg)</b>	Placebo	66.8 (81.5)	36.6 (15.7;89.6)	79.7 (105.7)	36.6 (13.6;111.9)	12.9 (52.9)	0.485	0.297
	Antioxidant	60.9 (58.7)	40.7 (17.8;84.8)	60.6 (69.3)	31.6 (18;78)	-0.3 (54.9)	0.427	
<b>Selenium (μg)</b>	Placebo	59.4 (42.1)	47.2 (33.4;86.1)	70.8 (44.7)	67.5 (32.8;100.5)	11.4 (25.4)	0.084	0.180
	Antioxidant	71.1 (62.8)	57.4 (24.3;105.5)	58.1 (40)	52.5 (24.4;88.6)	-13.1 (64.3)	0.997	
<b>Zinc (mg)</b>	Placebo	7.33 (3.12)	6.32 (5.22;9.32)	7.4 (3.94)	6.46 (3.93;10.4)	0.07 (2.97)	0.606	0.552
	Antioxidant	6.53 (3.34)	6.27 (5;8.17)	6.79 (3.64)	5.99 (3.88;9.13)	0.26 (3.83)	0.755	
<b>cystine (mg)</b>	Placebo	391.1 (310.7)	258.7 (201.4;583.9)	401.8 (302.1)	345.4 (166;519.9)	10.7 (239)	0.465	0.536
	Antioxidant	442.3 (361.5)	249.8 (142.4;824.6)	404.7 (333.3)	289 (146.6; 588.8)	-37.5 (333.6)	0.926	

<sup>1</sup>*p*-value for the time effect (using logarithmic transformations); <sup>2</sup>*p*-value from repeated measurements ANOVA. The effects reported include differences between the groups in the degree of change (using logarithmic transformations)